 A couple of months back we discussed the decline in the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, following negative data around Tofersen - an experimental drug for patients with amyotrophic lateral sclerosis. 